Protein Dynamic Solutions Inc. was founded by biopharmaceutical scientists to fulfill a need for improved Critical Quality Attribute (CQA) analysis.
Our team members have worked in, and served, the biologics industry for decades across the entire drug discovery and development pipeline. We understand the absolute need for, and inherent challenges of, therapeutic protein characterization and we have developed and delivered numerous novel technologies that have contributed to better pharmaceutical solutions for patients around the world.
To provide state-of-the-art characterization tools for protein developers to ensure drug product viability and patent protection.
We aim to improve the quality of life of patients worldwide by providing tools to biopharmaceutical developers to speed time to market of drugs with improved design, formulation and quality.
PDS is currently providing early access to its breakthrough ProteinMentor platform technology.
Contact our team to learn more about our analytical services or to schedule an evaluation of our platform.
Thirty years developing cutting-edge solutions for protein characterization, with 20 years in pharmaceutical bioprocessing. M.S. & Ph.D. at Rutgers University, Post Doc at Mayo Clinic. Patented innovator in protein aggregation & tenured faculty member at the University of Puerto Rico.
Strong network in the biologics community, having trained a generation of students in biotechnology, protein spectroscopy and characterization for subsequent employment in the biopharmaceutical industry
Twenty years commercialization of life science technologies, with focus on innovative tools and services for the pharmaceutical industry. Track record of driving growth for emerging organizations, including as a founder of BIOCIUS (RapidFire Mass Spec for high throughput drug discovery), through to acquisition by, and integration into, Agilent Technologies. Strong network across the Life Science area; recently as Senior Director of Business Development at SCIEX, a Danaher company.
Dr. Canto is a practicing urologist and an experienced, accredited investor and entrepreneur overseeing a portfolio of life sciences ventures. He is the Laboratory Director and Principal Investigator at Auxilio BioLab and the President and Chief Scientific Officer of Antilles Research Institute, Inc. A graduate of the Baylor College of Medicine and Harvard Medical School, he is recipient of numerous research and teaching awards and author of peer-reviewed book chapters and scientific papers.
Mr. Viso is Chairman and Chief Executive Officer of Grupo VL, LLC. Mr. Viso was a member of the Board of Directors of Patheon Inc. (acquired by ThermoFisher in 2017), a leading multinational firm that manufactures prescription drugs for biopharmaceutical companies and successfully operates three manufacturing sites in Puerto Rico, employing more than 1,600 associates. Mr. Viso was President and General Manager of SmithKline (now GSK) operations in Puerto Rico.
Mr. Lockwood has three decades of experience in corporate, investment banking and entrepreneurial, multinational investor relations. Credit rating experience in life sciences, technology ventures, infrastructure and public finance sectors includes: Co-Founder of private equity funds of funds, CEO and co-founder of development banks, bioclusters and technology funds. Advisor to Abbvie, HP, McKinsey, Goldman Sachs, Thomas H. Lee, Citibank, Brookings.
Dr. Noda is CSO & Sr VP at MHG. Inc. A former Research Fellow of 34 years with Procter & Gamble, Dr. Noda holds over 85 granted patents in spectroscopy. BS, MS, M.Phil. and PhD Columbia University & D.Sc. University of Tokyo, he is recipient of awards including American Chemical Society, Society for Applied Spectroscopy, Chinese Chemical Society, Chinese Optical Society & Coblentz Society. Honorary Adjunct Professor at Tsinghua University in Beijing.
Former Director for Research at Mayo Clinic, and former Director/Founder of the Mayo Clinic Cancer Center. Research priorities include structure, dynamics and function of proteins. Member of the Public Policy & Compliance Committee and of Science & Technology Committee. PhD Mayo Graduate School, MA and BA the University of Oxford, MD with Honors from the University of the West Indies.
Mr. Martin was Senior VP for Global Scientific Affairs at Pall Corporation (Danaher).
Awarded the Thought Leader of the Decade prize by Bioprocess International magazine, he has also received awards from the Parenteral Drug Association and BioProcess Systems Alliance, where he served as Chairman. He is an Expert Panel Member of the United States Pharmacopoeia (USP) and a contributor to USP, ASTM, ISO and PDA standards.